Second-line therapies in advanced hepatocellular carcinoma following first-line atezolizumab and bevacizumab: multicenter single institution cohort experience.
Marell P, Kournoutas I, Gile J, Peersen A, Shah P, Babiker H, Kankeu LF, Washburn L, Graham R, Truty M, Starlinger P, Halfdanarson T, Jin Z, Jatoi A, McWilliams R, Borad M, Bekaii-Saab TS, Mahipal A, Ou FS, Tran NH.
Marell P, et al.
Oncologist. 2024 Dec 14:oyae342. doi: 10.1093/oncolo/oyae342. Online ahead of print.
Oncologist. 2024.
PMID: 39674576
Free article.